Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Ei-lääkehoito vs farmakologinen hoito ei-akuuttiin lannelevytyrälle

keskiviikko 16. syyskuuta 2026 päivittänyt: Jaseng Medical Foundation

Ei-lääkehoidon ja ei-akuutin lannelevytyrän lääkehoidon vertaileva tehokkuus: monikeskeinen, käytännöllinen satunnaistettu, kontrolloitu, rinnakkain ryhmitelty tutkimus

This is a randomized controlled study comparing non-pharmacological treatment to proactive pharmacological treatment for patient with non-acute lumbar disc herniation with moderate or higher levels of pain. The study involves 200 adult patients aged 19-69, with 50 patients from each participating hospital. Patients will be randomly assigned to either the non-pharmacological treatment group or the pharmacological treatment group 1:1 ratio. Specific interventions will be determined by doctors and Korean medicine doctors without predefined treatment strategies. The non-pharmacological treatment include acupuncture, electroacupuncture, spinal manual therapy and motion style acupuncture. The pharmacological treatment include medication prescription, injection, and nerve block. Treatment period is 8 weeks, and f/u for 3 years.

Tutkimuksen yleiskatsaus

Tila

Rekrytointi

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

This is a pragmatic, multi-centered, randomized controlled, parallel-grouped study aiming to compare the effectiveness of a non-pharmacological treatment strategy and a active pharmacological treatment strategy in managing non-acute lumbar disc herniation with moderate or higher levels of pain persisting for more than one month in adult men and women aged 19 to 69 years.

The study will include 200 patients with lumbar disc herniation, with 50 patients from each of the participating hospitals (Jaseng Hospital of Korean Medicine, Daejeon Jaseng Hospital of Korean Medicine, Bucheon Jaseng Hospital of Korean Medicine, Haeundae Jaseng Hospital of Korean Medicine, competitively recruited). The patients will be assigned in a 1:1 ratio to receive either non-pharmacological treatment (100 patients) or active pharmacological treatment (100 patients) in a pragmatic randomized controlled design. The specific interventions for each group will be determined based on clinical judgment by the doctors and Korean medicine doctors involved in the study, without predefining the treatment strategies. The treatment methods, including acupuncture, electroacupuncture, spinal maunal therapy and motion style acupuncture, will be recorded in the case report form for comparative analysis.

For the non-pharmacological treatment group, patients will be recommended to receive non-pharmacological treatment based on TKM. The frequency and specifics of the treatment will be determined by the clinical judgment of the doctors and Korean medicine doctors based on the patient's symptoms, MRI images, and clinical improvement. The treatment will be conducted twice a week for a total of eight weeks, but the frequency may be adjusted according to the patient's condition. Concurrent therapies and adjuvant therapies can be freely chosen by the patients, and the details will be recorded in the case report form.

For the pharmacological treatment group, patients will be educated about proactive pharmacological treatment and recommended to receive pharmacological treatment. The specific pharmacological interventions, such as prescription medication, injection therapy, and nerve block, will be determined by the doctors based on the patient's symptoms, imaging results, and clinical judgment. The details of the prescribed medication, dosage, administration route, and duration will be recorded in the case report form. Similar to the non-pharmacological treatment group, concurrent therapies and adjuvant therapies can be chosen by the patients, and the details will be recorded.

The treatment frequency for the pharmacological treatment group will also be twice a week for a total of eight weeks, with adjustments based on the patient's condition. The effectiveness of the treatment strategies will be assessed through weekly evaluations of the patients' symptoms and treatment progress.

It should be noted that patients are not obligated to strictly follow the assigned treatment strategy, as this is a study recommending a particular treatment strategy rather than enforcing it as a protocol violation.

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

200

Vaihe

  • Ei sovellettavissa

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

  • Etelä -Korea
      • Busan, Etelä -Korea
        • Rekrytointi
        • Haeundae Jaseng Hospital of Korean Medicine
        • Ottaa yhteyttä:
          • Hyun Woo Cho, PhD
        • Ottaa yhteyttä:
      • Daejeon, Etelä -Korea
        • Rekrytointi
        • Daejeon Jaseng Hospital of Korean Medicine
        • Ottaa yhteyttä:
    • Gangnam-Gu
      • Seoul, Gangnam-Gu, Etelä -Korea, 135-896
        • Rekrytointi
        • Jaseng Hospital of Korean Medicine
        • Ottaa yhteyttä:
    • Gyeonggi-do
      • Bucheon-si, Gyeonggi-do, Etelä -Korea, 14598
        • Rekrytointi
        • Bucheon Jaseng Hospital of Korean Medicine
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

19 vuotta - 69 vuotta (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • aged 19 to 69 years.
  • lower back pain that has persisted for at least 1 month.
  • a Numeric Rating Scale (NRS) score of 5 or higher for either lower back pain or radiating leg pain over the past three consecutive days.
  • confirmed lumbar disc herniation on MRI that can explain the lower back pain.
  • who have provided written informed consent and agreed to participate in the clinical study.

Exclusion Criteria:

  • diagnosed with specific severe diseases that could be the cause of lower back pain or leg pain (e.g., spinal metastasis, acute fractures, and spinal dislocation).
  • showing progressive neurological deficits or severe neurological symptoms.
  • with pain originating from soft tissue disorders other than the spine (e.g., tumors, fibromyalgia, rheumatoid arthritis, gout).
  • with other chronic conditions (e.g., stroke and myocardial infarction, renal disease, diabetic neuropathy, dementia, epilepsy) that may interfere with the treatment effect or result interpretation.
  • taking steroids, immunosuppressive drugs, psychiatric medications, or other medications that may impact the study results.
  • acupuncture or nerve block treatment is inappropriate or unsafe, such as those with a history of bleeding disorders, receiving anticoagulant therapy, or diagnosed with uncontrolled diabetes.
  • taken non-steroidal anti-inflammatory drugs (NSAIDs) or other pain-affecting drugs or received acupuncture treatment within the past 5 days.
  • Pregnant women, those planning pregnancy, or breastfeeding women.
  • within 3 months after lumbar surgery.
  • who have not completed participation in another clinical study within the past month or have plans to participate in another clinical study within 6 months from the selection date or during the study participation and follow-up period.

Inability to provide written informed consent.

- Other cases where the researchers determine that participation in the clinical study would be difficult.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Yksittäinen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Non-pharmacological treatment strategy

Interventions: Non-pharmacological treatment include acupuncture, electroacupuncture, spinal manual therapy, and motion style acupuncture treatment.

Frequency: Not specified (Twice a week recommended) Duration: Eight weeks.
Menettely: non-pharmacological treatment strategy

Acupuncture, elctroacupuncture, spinal manual therapy, motion style acupucnture treatment
Active Comparator: Pharmacological treatment strategy

Interventions: Active pharmacological treatment involving prescription medication, injection therapy, or other pharmacological interventions.

Frequency: Not specified (Twice a week recommended) Duration: Eight weeks.
Menettely: pharmacological treatment strategy

Prescription medication, injection therapy, nerve blocks, or other pharmacological interventions commonly used for managing lumbar disc herniation.

This group is treated using the above treatment strategies, and no drug is specified.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Oswestry Disability Index (ODI)
Aikaikkuna: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The Oswestry Disability Index (ODI) is a questionnaire used to assess the functional status and degree of disability caused by lower back pain. It consists of 10 items that evaluate various aspects of daily activities and mobility. Each item is rated on a 6-point scale, with higher scores indicating a greater level of disability.

From 0 to 100. Higher scores mean a worse outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
Numeric Rating Scale for Pain of Dominant Change (NRS for DC)
Aikaikkuna: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

The study will evaluate the intensity of lower back pain and radiating leg pain using the Numeric Rating Scale (NRS). Patients will rate their pain levels on a scale from 0 to 10, where 0 represents no pain and 10 represents the most severe imaginable pain. The NRS for Dominant Change (NRS-DC) will be calculated as the higher value between the change in NRS scores from baseline for lower back pain and radiating leg pain. The NRS-DC will serve as a key evaluation indicator for pain intensity.
Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Recurrence
Aikaikkuna: Week 13, 26, 39, 52, Month 18, 24, 36

This study will confirm the recurrence of symptoms in patients through a yes or no response.
Week 13, 26, 39, 52, Month 18, 24, 36
Numeric Rating Scale (NRS) for Low Back Pain
Aikaikkuna: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

NRS is a pain scale in which the patient indicates their subjective pain as a whole number from 0 to 10. The participants are asked to report their low back pain and discomfort using NRS, where 0 indicates 'no pain or discomfort' and 10 indicates 'the most severe pain and discomfort imaginable.
Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36
Patient Global Impression of Change (PGIC)
Aikaikkuna: Week 9, 13, 26, 39, 52, Month 18, 24, 36

Participants rate the improvement after treatment on a 7-point Likert scale (1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse.)
Week 9, 13, 26, 39, 52, Month 18, 24, 36
Fear-Avoidance Beliefs Questionnaire (FABQ)
Aikaikkuna: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The fear-avoidance belief questionnaire (FABQ) is a questionnaire based on the fear-avoidance model of exaggerated pain perception. The FABQ measures patient's fear of pain and consequent avoidance of physical activity (PA) because of their fear.

Minimum 0 to maximum 66 scores. Higher score means a worse outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
Short Form-12 Health Survey version 2 (SF-12 v2)
Aikaikkuna: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The SF-12 consists of 12 questions across 8 domains, and higher scores indicate better health-related quality of life.

Ranging from 0 to 100, higher score means a better outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
EuroQol-5 Dimension (EQ-5D-5L)
Aikaikkuna: Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36

The EQ-5D-5L consists of 5 questions (mobility, self-care, usual activities, pain, anxiety/depression) that ask about the current state of health, and answers each question with 5 likert. (1=I have no problems about, 2=I have slight problems about, 3=I have moderate problems about, 4=I have severe problems about, 5=I am unable to about) Ranging from 0 to 1, higher score means a better outcome.
Week 1, 5, 9, 13, 26, 39, 52, Month 18, 24, 36
Credibility and Expectancy
Aikaikkuna: Baseline

The study will measure the level of trust and expectation regarding the effectiveness of the treatment through two questions:

On a scale from 0 to 10, how much do you believe that traditional herbal medicine treatment will alleviate your symptoms? On a scale from 0 to 10, how much do you believe that drug therapy will alleviate your symptoms? 0 indicates no belief or expectation, and 10 indicates full belief and high expectation.
Baseline
Intention to Treat
Aikaikkuna: Week 9

Evaluate participants' intentions if they are willing to receive non-pharmacological treatment strategies or pharmacological treatment strategies in the future on a scale from 0 to 9. 0 indicates no intention, and 10 indicates full belief and high intention.
Week 9
Work Productivity and Activity Impairment-Specific Health Problem
Aikaikkuna: Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Productivity loss will be assesed by WPAI-SHP. Through the WPAI questionnaire, the overall work productivity, which is a concept combining absenteesim and presenteeism, as well as employment will be investigated and used as outcomes.
Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36
Classification of Disc Degeneration
Aikaikkuna: Week 1, 26, 52, Month 24, 36

Classify the degree of disc degeneration based on the Pfirrmann grading system.
Week 1, 26, 52, Month 24, 36
Stages to a Disc Herniation
Aikaikkuna: Week 1, 26, 52, Month 24, 36

Classify the stage of disc herniation as bulging, protrusion, extrusion, or sequestration/migration.
Week 1, 26, 52, Month 24, 36
Herniated Disc Areas
Aikaikkuna: Week 1, 26, 52, Month 24, 36

Measure the area of the most significant transverse plane slice of the herniated disc on MRI.
Week 1, 26, 52, Month 24, 36
Cost Data Survey
Aikaikkuna: Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Measure various cost items related to the treatment, including medical costs, non-medical costs, time costs, and productivity loss costs.
Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 13, 26, 39, 52, Month 18, 24, 36

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Jaseng Medical Foundation

Tutkijat

  • Opintojohtaja: In-Hyuk Ha, Dr, Jaseng Medical Foundation

Julkaisuja ja hyödyllisiä linkkejä

Tutkimusta koskevien tietojen syöttämisestä vastaava henkilö toimittaa nämä julkaisut vapaaehtoisesti. Nämä voivat koskea mitä tahansa tutkimukseen liittyvää.

Yleiset julkaisut

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Keskiviikko 9. elokuuta 2023

Ensisijainen valmistuminen (Arvioitu)

Tiistai 31. joulukuuta 2030

Opintojen valmistuminen (Arvioitu)

Tiistai 31. joulukuuta 2030

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 20. heinäkuuta 2023

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Tiistai 29. elokuuta 2023

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 6. syyskuuta 2023

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 21. syyskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Keskiviikko 16. syyskuuta 2026

Viimeksi vahvistettu

Tiistai 1. syyskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • JS-CT-2023-02

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa